Hypoglycaemic agents

Oral hypoglycaemic agents Oral blood glucoselowering drugs Insulin secretagogues Antihypergly-caemics... 

Murcia-Soler M, Perez-Gimenez F, Naldo-Molina R, Salabert-Salvador MT, Garcla-March FJ, Cercos-del-Pozo RA et al. QSAR analysis of hypoglycaemic agents using the topological indices. J Chem Inf Comput Sci 2001 41 1345-54. 

Arce A et al. Changes in the liver protein pattern of female Wistar rats treated with the hypoglycaemic agent SDX PGU 693. Life Sci 1998 63 2243-2250. 

Some 2-amino derivatives (36) have been reported to show local anaesthetic, parasympathomimetic, long-lasting myorelaxant, brief hypotensive and mild antiarrhythmic activities [83]. Analogous cyclic amidines (37) with a 3-phenyl group were examined for potential hypoglycaemic agents [7]. Ten of 16 compounds showed weak to moderate activity in the rat. The most active compound was (37, R1 = OMe R2 = R3 = H, R4 = cyclopropyl), although it was less active than tolbutamide [84]. 

M. Fujimaki, N. Ishigaki, H. Hakusui, Metabolic Fate of the Oral Hypoglycaemic Agent, Midaglizole, in Rats , Xenobiotica 1989, 19, 609-625. 

Repaglinide is a newer oral hypoglycaemic agent, indicated in type 2 diabetes either in combination with metformin or as monotherapy. Repaglinide stimulates insulin release. 

Are there literature data supporting that the drug does not cross the placenta If so, the drug is not likely to cause direct harm to the foetus (but may still act indirectly, as with e.g. hypoglycaemic agents). 

II.f.2.1. Oral hypoglycaemic agents. There are now five groups of orally active drugs available to lower blood glucose in clinical practice (Table 2). These are sulphonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones, and the incretin derivatives. 

Comparison of repaglinide vs gliclazide in combination with bedtime NPH insulin in patients with type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabetic Med 2003 20 935 11. 

Goudswaard AN, Stolk RP, de Zuithoff P, Valk HW, Rutten GE. Starting insulin in type 2 diabetes continue oral hypoglycaemic agents J Fam Pract 2004 53 393-9. 

Bertini AM, Silva JC, Taborda W, Becker F, Bebber FRL, Viesi JMZ, Aquim G, Ribeiro TE. Perinatal outcomes and the use of oral hypoglycaemic agents. J Perinat Med 2005 33 519-23. 

Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2004 CD003418. 

Monnier et al.519 had further comments on each. In this chapter, attention is paid especially to trapping agents and intervention through enzymes, ending up with mention of a recently demonstrated hypoglycaemic agent. 

Anderson NL, Taylor J, Hofmann JP, Esquer-Blasco R, Swift S, Anderson NG (1996) Simultaneus measurement of hundreds of liver proteins Application in assessment of liver function. Toxicologic Pathology 24(l) 72-76 Arce A, Aicher L, Wahl D, Anderson NL, Meheus L, Ray-mackers J, Cordier A, Steiner S (1998) Changes in the liver protein pattern of female wistar rats treated with the hypoglycaemic agent SDZ PGU 693. Life Science 63(25) 2243-2250... 

A modified amyhn, Pramlintide, is being investigated as a hypoglycaemic agent in early type 2 diabetes. It potently reduces glucagon secretion and therefore postprandial hyperglycaemia. 

---